araag2/HINT huggingface dataset:
Clinical trial NCT00004239 (phase 1, status: terminated)
Conditions: chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes
ICD codes: D47.1, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C96.20, C96.29, D47.09, D46.9, D46.C, D46.Z
Drugs: compound 506u78
SMILES: COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed hematologic malignancy that has failed
        standard therapy or for which no standard therapy exists, including, but not limited to,
        the following: Acute lymphocytic leukemia Acute myelogenous leukemia Chronic lymphocytic
        leukemia Chronic myelogenous leukemia Multiple myeloma Non-Hodgkin's lymphoma Hodgkin's
        disease No history of CNS disease, including carcinomatous meningitis

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CTC 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin: Groups 1-4: Less than 1.5 times
        upper limit of normal (ULN) Group 5: 1.5-4 times ULN Renal: Creatinine clearance: Groups 1
        and 5: Greater than 50 mL/min Group 2: 30-50 mL/min Group 3: Less than 30 mL/min Group 4:
        Less than 30 mL/min, requiring dialysis Neurologic: No history of grade 2 peripheral
        neuropathy No history of seizure disorder No history of neurologic dysfunction Other: Not
        pregnant or nursing Fertile patients must use effective contraception HIV negative

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy
        (e.g., interferon, monoclonal antibodies) No concurrent interleukin-11 for treatment or
        prevention of thrombocytopenia No concurrent prophylactic colony stimulating factors
        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for melphalan, carmustine,
        or mitomycin) At least 72 hours since prior hydroxyurea No prior 506U78 No other concurrent
        chemotherapy Endocrine therapy: At least 72 hours since prior glucocorticoids Concurrent
        continuation of steroids for adrenal failure allowed No concurrent hormones except for
        nondisease related conditions (e.g., insulin for diabetes) No concurrent dexamethasone or
        other steroidal antiemetics Radiotherapy: At least 4 weeks since prior radiotherapy No
        concurrent palliative radiotherapy No concurrent whole brain irradiation for documented CNS
        disease Surgery: Not specified Other: At least 72 hours since prior aspirin
Clinical trial NCT00553696 (phase 1, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: cisplatin, s-1, sunitinib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of gastric cancer

          -  Chemonaive patients

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients who meet the contra-indications of S-1 and Cisplatin.

          -  Prior chemotherapy failure patients
Clinical trial NCT00610246 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced cancer not eligible for curative treatment.

          -  A measurable lesion in the thorax, abdomen or pelvis.

          -  Normal organ and bone marrow function.

          -  Able to receive protocol prescribed radiation. Please refer to the protocol for
             detailed inclusion criteria.

        Exclusion Criteria:

          -  Overlap of treatment field with a previous radiation field.

          -  Inability to meet mandated normal tissue radiation dose constraints.

          -  Brain metastases (unless previously treated and controlled)

          -  Previous treatment with Sorafenib.

          -  Poorly controlled Hypertension.

          -  Unable to swallow sorafenib tablets.

          -  Intercurrent cardiac dysfunction.

          -  Uncontrolled intercurrent illness. Please refer to the protocol for detailed exclusion
             criteria.
Clinical trial NCT01507077 (phase 1, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: zgn-440, zgn-440 sterile diluent
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Obese but otherwise healthy females

          -  Non-childbearing potential (surgically sterile, post-menopausal, or receiving
             implanted or injectable contraceptive for at least 3 months)

          -  BMI ≥ 30 and ≤ 45 kg/m2

          -  Stable body weight during the past 2 months

        Exclusion Criteria:

          -  Use of weight loss agents in the past month

          -  History of eating disorder

          -  History of type 1 or type 2 diabetes mellitus

          -  Current smokers
Clinical trial NCT00108186 (phase 1, status: withdrawn)
Conditions: non-small-cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Reason stopped: 
    couldn't accrue patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed and surgically resectable non small cell lung cancer and
             subjects must be ineligible for or refuse, neoadjuvant therapy

        Exclusion Criteria:

        Hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration,
        chronic or concurrent use of steroids and renal insufficiency
Clinical trial NCT00372905 (phase 1/phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, bortezomib, ibritumomab tiuxetan
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    study was closed permanently before the accrual goal was met due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed follicular lymphoma

          -  CD20+ at time of diagnosis or subsequently

          -  More than 4 weeks since prior rituximab

          -  More than 3 weeks since prior anticancer therapy (6 weeks for nitrosourea or mitomycin
             C)

          -  More than 4 weeks since prior major surgery

          -  More than 2 weeks since prior investigational drugs

        Exclusion Criteria:

          -  AIDS-related lymphoma

          -  History or evidence of CNS involvement

          -  Pregnant or nursing

          -  known HIV positivity

          -  serious medical or psychiatric illness that would preclude study participation

          -  myocardial infarction within the past 6 months

          -  congestive heart failure, uncontrolled angina, severe uncontrolled ventricular
             arrhythmias, or ECG evidence of acute ischemia or active conduction system
             abnormalities

          -  known hypersensitivity to rituximab, bortezomib, boron, or mannitol

          -  prior autologous or allogeneic stem cell transplantation

          -  prior radioimmunoconjugate therapy or prior exposure to murine antibodies

          -  prior external-beam irradiation to > 25% of active bone marrow
Clinical trial NCT00392691 (phase 1, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ibritumomab tiuxetan, rituximab, melphalan, vinorelbine tartrate / g-csf
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-Hodgkin's lymphoma of any type

          -  CD20-positive disease

          -  Achieved partial or complete response to salvage treatment for relapse or refractory
             disease within the past 10 weeks

          -  Must have an indication for autologous stem cell transplantation

          -  Bone marrow infiltration < 25%

          -  No evidence of CNS involvement

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2 times ULN

          -  AST ≤ 2 times ULN

          -  Creatinine clearance > 50 mL/min

          -  No clinically significant cardiac disease, including any of the following:

               -  Unstable angina pectoris

               -  Significant arrhythmia

               -  Myocardial infarction within the past 3 months

          -  LVEF > 50%

          -  No clinically significant urinary tract obstruction

          -  No clinically significant pulmonary disease

          -  No serious underlying medical condition that would preclude study participation

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             adequately treated in situ cervical cancer

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 30 days since prior participation in another clinical trial

          -  No prior stem cell transplantation

          -  No prior radiolabeled antibodies, including for induction of disease remission

          -  No prior radiotherapy to ≥ 25% of the bone marrow

          -  No concurrent radiotherapy

          -  No other concurrent anticancer drugs

          -  No other concurrent investigational drugs
Clinical trial NCT00706069 (phase 1, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vinorelbine oral, capecitabine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic breast cancer

          -  Age 18-75 years

          -  Bidimensionally measurable or evaluable disease

          -  Performance status (PS) 0-2 (ECOG)

          -  Patients with reproductive potential must use an adequate contraceptive method (e.g.,
             abstinence, intrauterine device, oral contraceptives, barrier device with spermicide,
             or surgical sterilization) during treatment and for three months after completing
             treatment

          -  Adequate liver (serum bilirubin <1.5 times the upper normal limit, AST and ALT <2.5
             times the UNL in the absence of demonstrable liver metastases, or <5 times the upper
             normal limit in the presence of liver metastases); adequate renal function (serum
             creatinine <1.5 times the upper normal limit); and adequate bone marrow
             function(neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)

          -  At least three weeks from completion of irradiation

          -  Life expectancy ≥ 12 weeks

          -  Patients able to take oral medication

          -  written informed consent

        Exclusion Criteria:

          -  Active infection

          -  Brain metastases

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  Malnutrition (loss of ≥ 20% of the original body weight)

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
Clinical trial NCT00672412 (phase 1/phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: gpo-vir z30 tablet, lamivudine, nevirapine, zidovudine
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Weigh between 6 and 30 kilograms

          -  HIV infected

          -  Receiving HAART regimen of NVP and 2 NRTIs. More information on this criterion can be
             found in the protocol.

          -  Agree to use two appropriate forms of contraception. More information on this
             criterion can be found in the protocol.

          -  Ability to swallow study drugs

          -  Willing to be hospitalized for 12-hour intensive PK study

          -  Agree to use two appropriate forms of contraception. More information on this
             criterion can be found in the protocol.

          -  Parent or legal guardian able and willing to provide written informed consent

        Exclusion Criteria:

          -  Certain abnormal laboratory values. More information on this criterion can be found in
             the protocol.

          -  Vomiting or diarrhea (greater than Grade 2) within 30 days prior to study entry

          -  History of immunologic failure. More information on this criterion can be found in the
             protocol.

          -  Current treatment for an acute serious bacterial, viral, or opportunistic infection

          -  History of dose-limiting toxicity requiring treatment discontinuation of any of the
             study drugs

          -  Hypersensitivity to study drugs

          -  Surgical or medical problem affecting gastrointestinal motility or absorption or liver
             function

          -  Treatment with experimental drugs within 30 days prior to study entry

          -  Acute hepatitis

          -  Chemotherapy for active malignancy

          -  Any clinically significant diseases or findings during the screening medical history
             or physical examination that, in the opinion of the investigator, may interfere with
             the study

          -  Pregnant
Clinical trial NCT00101842 (phase 1/phase 2, status: completed)
Conditions: carcinoma, transitional cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: pemetrexed, gemcitabine, platinol
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy-proven metastatic bladder cancer

          -  No prior chemotherapy for metastatic disease except before or after surgery, which was
             completed 6 months before enrollment

          -  Prior radiation allowed, if it is not the only site of measurable disease and if
             completed 3 weeks before enrollment

          -  18 years of age and older

        Exclusion Criteria:

          -  Pure adeno- or squamous urothelial cancer

          -  Brain metastases that causes symptoms

          -  Have not received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication

          -  Inability to take dexamethasone, folic acid or vitamin B12, according to the protocol

          -  Clinically relevant fluid collection in the lungs or abdomen that cannot be controlled
Clinical trial NCT00428194 (phase 1, status: withdrawn)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: cisplatin, erlotinib hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    withdrawn due to lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of squamous cell carcinoma of the cervix

               -  Stage IB-IVA disease

          -  Scheduled to undergo standard radiotherapy and receive weekly cisplatin

          -  ECOG performance status 0-2

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 1 week after
             completion of study treatment

          -  Must be able to take oral medication

        Exclusion Criteria:

          -  Malabsorption syndrome

          -  Serious underlying medical condition that would impair the ability of patient to
             receive treatment

          -  Known hypersensitivity to erlotinib hydrochloride

          -  Psychological, familial, sociological, or geographical conditions that would preclude
             study compliance

          -  Less than 21 days since prior nonapproved or investigational drugs

          -  Prior chemotherapy

          -  Prior radiotherapy

          -  Prior anti-epidermal growth factor receptor treatment

          -  Prior gastrointestinal surgery that limits absorption (i.e., requiring total
             parenteral nutrition)

          -  Concurrent use of any of the following agents and therapies:

               -  Other antineoplastic or antitumor agents

               -  Other chemotherapy

               -  Other investigational agents

               -  Radiotherapy

               -  Immunotherapy

               -  Anticancer hormonal therapy
Clinical trial NCT00225121 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pf-00299804
SMILES: COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Malignant solid tumor for which there is no currently approved treatment

          -  Adequate bone marrow, liver, cardiac, and kidney function

        Exclusion Criteria:

          -  Cardiac disease

          -  Anticancer therapy within 4-6 weeks (depending on therapy)

          -  Pregnant or breast-feeding
Clinical trial NCT00427414 (phase 1, status: terminated)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: liposomal daunorubicin citrate
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Reason stopped: 
    terminated due to slow accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed Kaposi's sarcoma (KS) involving the following:

               -  Skin

               -  Lymph nodes (palpable disease only)

               -  Oral cavity

          -  Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used
             as indicator lesions

          -  Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy

          -  Serologically confirmed HIV positivity

          -  Concurrent antiretroviral therapy required, except for patients who have exhausted all
             available treatment options

               -  Must be on a stable dose for ≥ 4 weeks

        PATIENT CHARACTERISTICS:

          -  Life expectancy ≥ 3 months

          -  No other neoplasia requiring cytotoxic therapy

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after completion of study treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior anthracycline therapy

          -  At least 4 weeks since prior antineoplastic treatment for KS, including any of the
             following:

               -  Chemotherapy (6 weeks for nitrosoureas or mitomycin C)

               -  Radiotherapy

               -  Local therapy

               -  Biological therapy

               -  Investigational therapy

          -  At least 60 days since prior local therapy of any KS indicator lesion unless lesion
             has clearly progressed since treatment

          -  No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific
             treatment
Clinical trial NCT00048399 (phase 1/phase 2, status: terminated)
Conditions: graft failure
ICD codes: T86.831, T86.821
Drugs: fludarabine, campath 1h, fk506
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Reason stopped: 
    accrual was slow
  
Eligibility criteria:

        INCLUSION CRITERIA

          -  Diagnosis of engraftment failure either primary or secondary, following allogeneic
             transplantation. Graft failure is defined as absolute neutrophil count < 500/mm3
             and/or platelet count < 20,000/mm3. Primary graft failure is defined as failure to
             maintain absolute neutrophil count > / = 500/mm3 for 3 consecutive days following
             allogeneic transplantation. Secondary graft failure is defined as failure to sustain
             an absolute neutrophil count > / = 500/mm3 after attainment of primary engraftment or
             failure to sustain platelet count > / = 20,000/mm3 despite neutrophil engraftment. For
             SCID patients, graft failure is defined as failure to recover > / = 500/mm3 T-cells
             and/or failure to generate satisfactory response to in vitro mitogen stimulation. For
             patients with genetic diseases, engraftment failure is defined as donor chimerism
             insufficient to correct or overcome the genetic or metabolic deficiency.

          -  Available Healthy Donor without any contraindications for donation (5/6 or 6/6 related
             donor or 5/6 or 6/6 unrelated donor (molecular typing for DRB1)

          -  Age between birth and 65

          -  For women of childbearing potential, negative pregnancy test

        EXCLUSION CRITERIA

          -  Pregnant and lactating women or women unwilling to use contraception.

          -  Uncontrolled intercurrent infection

          -  Refractory AML or ALL

          -  Untreated Blast Crisis for CML

          -  Uncontrolled High-grade lymphoproliferative disease/lymphoma

          -  Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)

          -  Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)

          -  Hemodialysis dependent

          -  Active Hepatitis or cirrhosis with total bilirubin, SGOT, or SGPT greater than 3 x
             normal.

          -  Concurrent solid organ malignancy not in remission, except for Stage 0 or A prostate
             cancer.

          -  Unstable Cerebral vascular disease and recent hemorrhagic stroke (less than 6 months)

          -  Active CNS disease from hematological disorder.